NEW YORK (GenomeWeb) – French immuno-oncology diagnostics firm HalioDx announced today that it has closed an €18.5 million ($22.7 million) Series B financing round.
Investors in the financing— which follows a €7.5 million Series A round at the time of the company's formation in March 2015 — included Bpifrance, Capricorn Venture Partners, and Amundi Private Equity Funds, as well as existing investors MI Care, Sham Innovation Santé/Turenne, BNP Paribas Development, and Sofipaca.
HalioDx said that the new investment would be used to continue development of its CE-IVD marked Immunoscore colon cancer assay — which measures the density of two T lymphocyte populations to help physicians assess disease prognosis — and to advance Immunoscore assays in additional cancer types. The company also plans to establish commercial operations in the US.
"This Series B financing will enable us to execute our plans faster and enter efficiently the US market," HalioDx CEO Vincent Fert said in a statement. "I am looking forward to see Immunoscore ... in oncologists' routine practice to manage prescriptions across multiple cancer indications."